{"product_id":"rmd-business-model-canvas","title":"ResMed Inc. (RMD): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas for ResMed Inc. gives you a practical, research-based view of how the company creates and captures value across sleep devices, software, and out-of-hospital care. You will see the key drivers behind its personalized CPAP comfort, connected-care ecosystem, \u003cstrong\u003e1.66B USD\u003c\/strong\u003e cash position, \u003cstrong\u003e140-country\u003c\/strong\u003e footprint, FDA and supplier partnerships, and revenue streams from sleep devices, masks and accessories, residential care software, out-of-hospital software, and international therapy sales.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\u003cp\u003eResMed Inc. sells into more than \u003cstrong\u003e140 countries\u003c\/strong\u003e, so its key partnerships have to support data integration, regulatory clearance, and supply continuity at global scale. The most important partnership layers in late 2025 are ŌURA sleep data integration, FDA and other regulators, and the suppliers that provide electronic parts, packaging, and freight capacity.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership layer\u003c\/td\u003e\n\u003ctd\u003eReal-life facts\u003c\/td\u003e\n\u003ctd\u003eBusiness model impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eŌURA sleep data partnership\u003c\/td\u003e\n\u003ctd\u003eConsumer sleep tracking partner; wearable ring platform; sleep and readiness data are collected continuously\u003c\/td\u003e\n \u003ctd\u003eExtends sleep data capture beyond the bedside device and can improve patient engagement across the care pathway\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA and regulatory authorities\u003c\/td\u003e\n\u003ctd\u003eU.S. FDA, plus other national regulators in markets such as Australia, the European Union, the United Kingdom, Canada, and Japan\u003c\/td\u003e\n \u003ctd\u003eControls product clearance, labeling, quality systems, and market access for medical devices\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElectronic component and logistics suppliers\u003c\/td\u003e\n \u003ctd\u003eSemiconductors, sensors, motors, plastics, packaging, and freight capacity are sourced through external suppliers and carriers\u003c\/td\u003e\n \u003ctd\u003eSupports device production, shipment reliability, and inventory availability\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eŌURA sleep data partnership\u003c\/strong\u003e matters because ResMed's value depends on more than the mask and device. Sleep care now includes longitudinal data, adherence behavior, and user feedback outside the clinic. ŌURA's ring format adds a second data stream that can sit alongside treatment data from ResMed devices. That kind of partnership is useful in academic analysis because it shows how a medical-device company can move closer to a data-enabled care model without owning every data source itself.\u003c\/p\u003e\n\n\u003cp\u003eThe partnership logic is simple: one company owns treatment delivery, while the other owns passive sleep tracking. The combination can support patient monitoring, coaching, and better self-management. For ResMed, that can strengthen retention and make its ecosystem harder to replace, especially when patients move between diagnosis, prescription, treatment, and follow-up.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eResMed's core device data is treatment data.\u003c\/li\u003e\n \u003cli\u003eŌURA's core data is consumer sleep and readiness data.\u003c\/li\u003e\n \u003cli\u003eCombined data can support adherence tracking and sleep behavior analysis.\u003c\/li\u003e\n \u003cli\u003eThe partnership can make the platform more sticky because the user is tied to both hardware and data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFDA and regulatory authorities\u003c\/strong\u003e are not optional partners. They define whether a device can be sold, how it must be tested, how it must be labeled, and how quality systems must operate. For a company like ResMed, this is a structural dependency because every product family must clear national rules before it can be commercialized. The U.S. FDA is the most important single authority for the U.S. market, but market access also depends on regulators in the European Union, Australia, the United Kingdom, Canada, and Japan.\u003c\/p\u003e\n\n\u003cp\u003eThe regulatory layer affects cost, timing, and product design. If a design change needs new review, development time rises. If a component supplier changes a material, ResMed may need updated validation. If a product falls under a safety or quality concern, recalls and remediation can affect revenue and margins. In plain English, regulatory partnership is really about permission to sell and permission to keep selling.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory item\u003c\/td\u003e\n\u003ctd\u003eNumber or threshold\u003c\/td\u003e\n\u003ctd\u003eWhy it matters\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. PAP adherence benchmark used in coverage decisions\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e hours per night on \u003cstrong\u003e70%\u003c\/strong\u003e of nights during a consecutive \u003cstrong\u003e30\u003c\/strong\u003e-day period within the first \u003cstrong\u003e90\u003c\/strong\u003e days\u003c\/td\u003e\n \u003ctd\u003eDrives how treatment is monitored and how reimbursement is maintained\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eObstructive sleep apnea severity threshold\u003c\/td\u003e\n \u003ctd\u003eApnea-hypopnea index of \u003cstrong\u003e5\u003c\/strong\u003e, \u003cstrong\u003e15\u003c\/strong\u003e, or \u003cstrong\u003e30\u003c\/strong\u003e events per hour\u003c\/td\u003e\n \u003ctd\u003eShapes diagnosis, treatment intensity, and device demand\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal operating footprint\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e140\u003c\/strong\u003e countries\u003c\/td\u003e\n \u003ctd\u003eRaises the number of regulatory regimes ResMed must manage\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eElectronic component and logistics suppliers\u003c\/strong\u003e are critical because ResMed's products depend on specialized parts and predictable shipping. Devices such as PAP systems and ventilators require electronics, sensors, motors, tubing, masks, plastics, and packaging. If any one of these inputs is delayed, the finished product can be delayed too. That means supplier concentration, lead times, and freight access directly affect operating performance.\u003c\/p\u003e\n\n\u003cp\u003eThe financial impact shows up in working capital, gross margin, and product availability. Working capital is the cash tied up in inventory and receivables. If ResMed carries more inventory to buffer shortages, cash use rises. If freight rates or component prices rise, margin pressure can follow. If supply improves, the company can ship faster and reduce stockouts. That is why supplier relationships are strategic, not just operational.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eElectronic component suppliers affect unit cost and production continuity.\u003c\/li\u003e\n \u003cli\u003ePackaging suppliers affect shipping protection and compliance.\u003c\/li\u003e\n \u003cli\u003eFreight and distribution partners affect delivery time and service levels.\u003c\/li\u003e\n \u003cli\u003eQuality-qualified suppliers reduce disruption risk after design changes or recalls.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply chain element\u003c\/td\u003e\n\u003ctd\u003eWhat it affects\u003c\/td\u003e\n\u003ctd\u003eBusiness risk if disrupted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSemiconductors and sensors\u003c\/td\u003e\n\u003ctd\u003eDevice function, monitoring, connectivity\u003c\/td\u003e\n \u003ctd\u003eProduction delay, redesign, shipment backlog\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMotors and airflow components\u003c\/td\u003e\n\u003ctd\u003ePressure delivery and treatment performance\u003c\/td\u003e\n \u003ctd\u003eProduct shortage, quality issues\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePackaging and freight partners\u003c\/td\u003e\n\u003ctd\u003eDelivery speed and protection in transit\u003c\/td\u003e\n \u003ctd\u003eHigher logistics cost, damaged goods, missed orders\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFor academic work, this chapter supports analysis of how ResMed depends on external partners to protect access, data quality, and supply reliability. The key point is that the business model is not built on product sales alone. It depends on a network of data, regulation, and supply relationships that keep devices legal, available, and clinically useful.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eResMed's key activities center on \u003cstrong\u003e2\u003c\/strong\u003e linked operating blocks: sleep and respiratory device development, and software-led care delivery. The company's model depends on designing hardware, connecting it to cloud software, and keeping patients and providers inside the therapy loop across more than \u003cstrong\u003e140\u003c\/strong\u003e countries.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCPAP and sleep device R\u0026amp;D\u003c\/strong\u003e is the core technical activity. ResMed develops positive airway pressure devices, masks, and connected therapy systems for obstructive sleep apnea and related breathing disorders. This matters because the company's hardware has to improve comfort, adherence, and data capture at the same time. In practice, that means work on quieter motors, smaller form factors, humidification, mask fit, leak reduction, and pressure-control algorithms. The company's device line includes CPAP and bilevel platforms used in home care and clinical settings.\u003c\/p\u003e\n\n\u003cp\u003eR\u0026amp;D is not only about product design. It also supports clinical validation, regulatory clearance, software integration, and replacement cycles. For a company selling recurring therapy equipment, better comfort and adherence can support repeat mask sales, higher device retention, and stronger software use. That makes R\u0026amp;D a direct driver of both patient outcomes and commercial renewals.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey activity\u003c\/th\u003e\n\u003cth\u003eWhat ResMed does\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003eReal-life anchor\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPAP and sleep device R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eDesigns sleep apnea devices, masks, and connected therapy systems\u003c\/td\u003e\n \u003ctd\u003eSupports adherence, replacement sales, and therapy quality\u003c\/td\u003e\n \u003ctd\u003eFounded in \u003cstrong\u003e1989\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI-enabled software and therapy optimization\u003c\/td\u003e\n \u003ctd\u003eUses cloud data and analytics to monitor therapy and support care decisions\u003c\/td\u003e\n \u003ctd\u003eRaises stickiness and helps providers manage patients remotely\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e reportable business segments\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and global distribution\u003c\/td\u003e\n\u003ctd\u003eMakes and ships devices, masks, and software-linked systems\u003c\/td\u003e\n \u003ctd\u003eRequired for supply reliability and global product availability\u003c\/td\u003e\n \u003ctd\u003eProducts sold in more than \u003cstrong\u003e140\u003c\/strong\u003e countries\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquiring and integrating sleep-health assets\u003c\/td\u003e\n \u003ctd\u003eBuys software and care-management assets and folds them into the platform\u003c\/td\u003e\n \u003ctd\u003eExpands the customer base and adds adjacent revenue streams\u003c\/td\u003e\n \u003ctd\u003eDevice plus software model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOut-of-hospital software operations\u003c\/td\u003e\n\u003ctd\u003eRuns cloud platforms for home-based and post-acute care workflows\u003c\/td\u003e\n \u003ctd\u003eCreates recurring revenue and deeper provider relationships\u003c\/td\u003e\n \u003ctd\u003eHome and post-acute care focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI-enabled software and therapy optimization\u003c\/strong\u003e is the second major activity. ResMed uses connected platforms to collect therapy data from patients using its devices and masks. That data supports remote monitoring, compliance tracking, and therapy adjustment. In plain English, the software helps doctors and care teams see whether therapy is working, whether the patient is using the device enough, and where treatment can improve. This matters because sleep apnea treatment depends on consistent nightly use, not just device sale.\u003c\/p\u003e\n\n\u003cp\u003eThe commercial logic is strong: software makes the device relationship longer and more valuable. It also helps ResMed sit closer to the care workflow, not just the product shelf. That can increase switching costs because providers who use the data tools are less likely to move to a different device ecosystem. For academic work, this is a clear example of hardware-plus-software integration in a health technology business model.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eTherapy data collection from connected devices\u003c\/li\u003e\n \u003cli\u003eRemote monitoring for patient adherence\u003c\/li\u003e\n\u003cli\u003eProvider dashboards for clinical follow-up\u003c\/li\u003e\n \u003cli\u003eSoftware-based support for therapy adjustments\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and global distribution\u003c\/strong\u003e are central because the business depends on reliable production of devices, masks, and accessories. ResMed must maintain quality control, regulatory compliance, and supply continuity across multiple product lines. That is especially important in medical devices, where product defects, delays, or shortages can affect treatment continuity and provider trust.\u003c\/p\u003e\n\n\u003cp\u003eThe global distribution footprint matters because sleep apnea is a worldwide condition and ResMed sells in more than \u003cstrong\u003e140\u003c\/strong\u003e countries. That scale gives the company access to multiple reimbursement systems, hospital networks, durable medical equipment providers, and direct-to-consumer channels. The challenge is that medical device manufacturing is capital- and compliance-intensive, so operating discipline affects margins and service levels. Manufacturing efficiency directly affects gross margin, which is the money left after production costs.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcquiring and integrating sleep-health assets\u003c\/strong\u003e is another key activity. ResMed has used acquisitions to expand beyond devices into software, care coordination, and post-acute workflows. This is important because it reduces dependence on a single product category and gives the company more ways to capture value across the treatment pathway. Integration matters as much as the deal itself. If the software, data, and workflow tools do not connect cleanly, the business does not get the full benefit of the acquisition.\u003c\/p\u003e\n\n\u003cp\u003eFrom a strategy angle, acquisition activity supports a broader care-platform model. Instead of selling one device and moving on, ResMed can link therapy initiation, monitoring, compliance, billing support, and downstream care management. That creates more recurring revenue opportunities and deeper integration with providers and home-care organizations.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eAcquiring software platforms tied to home-based care\u003c\/li\u003e\n \u003cli\u003eIntegrating patient data across devices and workflow tools\u003c\/li\u003e\n \u003cli\u003eCross-selling masks, devices, and software services\u003c\/li\u003e\n \u003cli\u003eAdding adjacent revenue streams outside pure hardware sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOut-of-hospital software operations\u003c\/strong\u003e are a major part of the business model because ResMed serves care settings outside the hospital, including home care and post-acute care. These software operations support scheduling, documentation, patient management, and care coordination. That matters because healthcare delivery is moving toward lower-cost settings, and software helps providers manage more patients without adding as much labor.\u003c\/p\u003e\n\n\u003cp\u003eIn business-model terms, this activity helps ResMed capture recurring subscription-like revenue instead of relying only on one-time hardware sales. It also increases switching costs because providers build workflows around the software. For academic analysis, this is a useful example of how a medical device company can move into healthcare information services without leaving its core market.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e2\u003c\/strong\u003e operational features make these activities economically important:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eRecurring use of connected devices and software services\u003c\/li\u003e\n \u003cli\u003eLonger customer relationships across the care pathway\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe key activities also depend on regulatory and clinical execution. Medical devices and software used in healthcare must work consistently, protect patient data, and meet local requirements in each market. That means ResMed's operating model has to combine engineering, quality assurance, software development, manufacturing control, and post-sale support in one system. For a company in this sector, those activities are not separate functions; they are the engine of the business model.\u003c\/p\u003e\n\u003ch2\u003eResMed Inc. - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eResMed Inc.'s key resources center on its connected care product base, its software platforms, its liquidity, its global distribution reach, and its intellectual property and clinical expertise. These resources support both device sales and recurring software and services revenue.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey resource\u003c\/td\u003e\n\u003ctd\u003eReal-life data point\u003c\/td\u003e\n\u003ctd\u003eBusiness model role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAirSense 11 and Smart Comfort tech\u003c\/td\u003e\n\u003ctd\u003eAirSense 11 platform; Smart Comfort features\u003c\/td\u003e\n \u003ctd\u003eCore connected sleep apnea device platform\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrixCare and Brightree software platforms\u003c\/td\u003e\n \u003ctd\u003eTwo software platforms in post-acute care and home medical equipment\u003c\/td\u003e\n \u003ctd\u003eRecurring software and workflow revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.66 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLiquidity for operations, investment, and capital allocation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal footprint\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e140-country\u003c\/strong\u003e footprint\u003c\/td\u003e\n\u003ctd\u003eDistribution reach and market access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents and clinical know-how\u003c\/td\u003e\n\u003ctd\u003ePatents, clinical data, and care expertise\u003c\/td\u003e\n \u003ctd\u003eProduct differentiation and barriers to entry\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAirSense 11\u003c\/strong\u003e is a central hardware resource because it anchors ResMed Inc.'s connected sleep-therapy platform. The device is tied to digital coaching, cloud connectivity, and patient adherence tracking, which makes the machine more than a one-time sale. In Business Model Canvas terms, this resource supports value creation through a device-plus-data model, not just equipment manufacturing.\u003c\/p\u003e\n\n\u003cp\u003eThe importance of AirSense 11 is not just the unit itself. The platform combines therapy hardware with connected features that support treatment monitoring and user experience. That matters because sleep apnea therapy depends on long-term adherence, and connected devices help ResMed Inc. monitor usage patterns and maintain clinical engagement.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAirSense 11\u003c\/strong\u003e is a flagship device platform.\u003c\/li\u003e\n \u003cli\u003eConnected functionality supports ongoing patient engagement.\u003c\/li\u003e\n \u003cli\u003eDevice performance links directly to recurring digital and service activity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMatrixCare\u003c\/strong\u003e and \u003cstrong\u003eBrightree\u003c\/strong\u003e are important software resources because they extend ResMed Inc. beyond hardware into workflow and administrative software. MatrixCare serves post-acute care, while Brightree supports home medical equipment and related care workflows. These platforms matter because software revenue is typically more recurring than device revenue and can deepen customer dependence through integrated operations.\u003c\/p\u003e\n\n\u003cp\u003eFor academic analysis, these platforms show how ResMed Inc. captures value from both sides of the care pathway. Hardware drives therapy delivery, while software helps manage ordering, billing, documentation, and patient coordination. That creates a broader business model than a pure medical device company.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware platform\u003c\/td\u003e\n\u003ctd\u003ePrimary use case\u003c\/td\u003e\n\u003ctd\u003eResource impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrixCare\u003c\/td\u003e\n\u003ctd\u003ePost-acute care software\u003c\/td\u003e\n\u003ctd\u003eWorkflow integration and recurring revenue\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrightree\u003c\/td\u003e\n\u003ctd\u003eHome medical equipment software\u003c\/td\u003e\n\u003ctd\u003eOperational control and customer stickiness\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003e$1.66 billion\u003c\/strong\u003e in cash is a major financial resource. Cash is the most flexible asset on the balance sheet because it can fund research and development, software investment, acquisitions, working capital, and debt service if needed. It also gives ResMed Inc. more room to manage supply chain needs and product development without relying only on external financing.\u003c\/p\u003e\n\n\u003cp\u003eIn plain English, cash gives the company optionality. Optionality means management can choose among several uses of capital instead of being forced into one path. For a company with both device and software businesses, that flexibility matters because it can support product launches, platform upgrades, and selective acquisitions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e140 countries\u003c\/strong\u003e is a significant global footprint resource. A wide country presence helps ResMed Inc. spread demand across regions, support multinational healthcare systems, and reduce dependence on any single market. It also supports scale in distribution, regulatory execution, and channel relationships.\u003c\/p\u003e\n\n\u003cp\u003eThe value of a global footprint is not just geographic reach. It also improves the company's access to clinicians, distributors, hospitals, homecare providers, and patients across different healthcare systems. That makes the footprint a strategic resource because it supports both device sales and software deployment.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e140-country\u003c\/strong\u003e reach supports international sales and distribution.\u003c\/li\u003e\n \u003cli\u003eBroader reach reduces reliance on one market.\u003c\/li\u003e\n \u003cli\u003eGlobal presence strengthens relationships with providers and channel partners.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatents and clinical know-how are core intangible resources for ResMed Inc. Patents protect product designs and technology features, while clinical know-how comes from long experience in sleep apnea, respiratory care, and connected patient monitoring. These assets matter because they make it harder for competitors to copy the company's products and workflow systems.\u003c\/p\u003e\n\n\u003cp\u003eClinical know-how is especially valuable in healthcare because product adoption depends on outcomes, usability, and provider trust. ResMed Inc.'s accumulated experience helps shape device design, software integration, and therapy support. That can improve product acceptance and reduce execution risk when introducing new features or platforms.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003ePatents support legal protection around product technology.\u003c\/li\u003e\n \u003cli\u003eClinical know-how supports product design and therapy adoption.\u003c\/li\u003e\n \u003cli\u003eIntangible assets raise switching costs for customers and providers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese resources work together as a connected system. AirSense 11 generates device demand, MatrixCare and Brightree extend the company into software, cash supports investment capacity, the \u003cstrong\u003e140-country\u003c\/strong\u003e footprint expands reach, and patents plus clinical expertise protect the model. That combination is what makes ResMed Inc.'s key resources stronger than a single-product or single-market setup.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eResMed reported $1,234,801,000\u003c\/strong\u003e in revenue for the quarter ended March 31, 2024, and \u003cstrong\u003e$4,685,910,000\u003c\/strong\u003e in revenue for the nine months ended March 31, 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePersonalized CPAP comfort and adherence\u003c\/strong\u003e is centered on making positive airway pressure therapy easier to use every night. ResMed's core value is not just selling a device; it is reducing therapy drop-off through masks, humidification, pressure delivery, and digital monitoring. For sleep apnea, adherence matters because therapy only works when the patient keeps using it. In business terms, that shifts value from one-time hardware sales toward recurring use of masks, cushions, tubing, humidifiers, and replacement parts.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOver \u003cstrong\u003e140 million\u003c\/strong\u003e people worldwide are estimated to have sleep apnea.\u003c\/li\u003e\n \u003cli\u003eRoughly \u003cstrong\u003e1 billion\u003c\/strong\u003e adults globally are estimated to have obstructive sleep apnea.\u003c\/li\u003e\n \u003cli\u003eMask fit, leak reduction, and pressure comfort are the main practical drivers of usage time.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eResMed's value proposition here is measurable because each extra hour of nightly use can improve the clinical usefulness of therapy and support long-term customer retention. For academic work, this is a strong example of how a medical device company monetizes adherence, not just equipment.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue proposition element\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eBusiness effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMask fit and comfort\u003c\/td\u003e\n\u003ctd\u003eHigher nightly use\u003c\/td\u003e\n\u003ctd\u003eBetter adherence lowers replacement churn risk\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapy data tracking\u003c\/td\u003e\n\u003ctd\u003eMore informed care\u003c\/td\u003e\n\u003ctd\u003eSupports clinical follow-up and device loyalty\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReplacement parts\u003c\/td\u003e\n\u003ctd\u003eRecurring revenue\u003c\/td\u003e\n\u003ctd\u003eBuilds a repeat purchase cycle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eConnected-care sleep health ecosystem\u003c\/strong\u003e combines devices, software, and remote monitoring. This matters because ResMed can link the patient, provider, and payer through digital data rather than relying only on in-clinic visits. The commercial value is higher retention, better service visibility, and stronger switching costs. The clinical value is earlier intervention when adherence falls or therapy settings need adjustment.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eResMed's digital health platforms connect therapy data across home and care settings.\u003c\/li\u003e\n \u003cli\u003eRemote monitoring supports treatment review without requiring the patient to travel.\u003c\/li\u003e\n \u003cli\u003eSoftware plus hardware creates multiple revenue points from the same patient relationship.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe business model effect is important: when a patient is already inside the connected ecosystem, the cost of changing suppliers rises. That makes the value proposition less about a single product feature and more about the full care loop.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHome-based and out-of-hospital care\u003c\/strong\u003e is one of ResMed's clearest economic advantages. Care at home is usually lower-cost than hospital-based treatment, and that aligns with payer pressure to reduce avoidable spending. It also fits patient preference because chronic therapy is easier to manage in the home than in a sleep lab or hospital setting.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHome sleep testing and home therapy reduce facility dependence.\u003c\/li\u003e\n \u003cli\u003eRemote care lowers travel time and appointment friction.\u003c\/li\u003e\n \u003cli\u003eChronic respiratory care can move from acute care to long-duration home care.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis value proposition matters because it supports a large addressable market. The global chronic respiratory and sleep-disordered breathing burden is high, and home-based care lets ResMed serve more patients with less infrastructure than traditional hospital-only models.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMask-first therapy and accessories\u003c\/strong\u003e means the mask is often the most critical part of the patient experience. A device can have the right pressure settings, but poor mask comfort can still cause leaks, skin irritation, and abandonment. ResMed's value proposition is to make the mask the primary comfort interface and then build a recurring replacement business around it.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMasks and cushions are wear items with repeat replacement demand.\u003c\/li\u003e\n \u003cli\u003eTubing, filters, humidifier chambers, and headgear add recurring sales.\u003c\/li\u003e\n \u003cli\u003eSmall improvements in comfort can affect usage more than small changes in device specs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor investors and students, this is a useful example of a razor-and-blades structure in health care. The initial device matters, but the replacement cycle can be more durable over time. That is why mask design is not a side business; it is a central value driver.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAccessory category\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRole in therapy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCommercial role\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMask cushions\u003c\/td\u003e\n\u003ctd\u003eSeal and comfort\u003c\/td\u003e\n\u003ctd\u003eFrequent replacement demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeadgear\u003c\/td\u003e\n\u003ctd\u003eStability and fit\u003c\/td\u003e\n\u003ctd\u003eReplacement and upgrade sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTubing and filters\u003c\/td\u003e\n\u003ctd\u003eAir delivery and cleanliness\u003c\/td\u003e\n\u003ctd\u003eRecurring consumables revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHumidifier chambers\u003c\/td\u003e\n\u003ctd\u003eMoisture control\u003c\/td\u003e\n\u003ctd\u003eAccessory attachment sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eNon-pharmacologic RLS therapy\u003c\/strong\u003e addresses restless legs syndrome without medication. The value proposition is relevant because many patients want symptom relief without drug side effects, dependence concerns, or drug-to-drug interactions. A non-drug approach can be especially useful for patients already managing sleep disorders or chronic respiratory conditions.\u003c\/p\u003e\n\n\u003cp\u003eWhere this matters strategically, it broadens ResMed's role from sleep apnea equipment supplier to a wider sleep-health company. That widens the use case for patients, clinicians, and care pathways that overlap with insomnia, periodic limb movement symptoms, and other sleep complaints.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRLS affects about \u003cstrong\u003e5% to 10%\u003c\/strong\u003e of adults in the United States.\u003c\/li\u003e\n \u003cli\u003eAbout \u003cstrong\u003e2%\u003c\/strong\u003e to \u003cstrong\u003e3%\u003c\/strong\u003e of adults have clinically significant symptoms.\u003c\/li\u003e\n \u003cli\u003eNon-drug therapy can be attractive when patients already take multiple medications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor academic analysis, this proposition shows how a company can expand from one disorder category into adjacent sleep-related conditions by using non-pharmacologic positioning, home use, and patient comfort as the common thread.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eResMed's late-2025 value proposition mix\u003c\/strong\u003e is best understood as a layered offer: devices, masks, consumables, software, and home-based care. The commercial strength comes from combining \u003cstrong\u003e$4,685,910,000\u003c\/strong\u003e in nine-month revenue capacity with recurring patient engagement rather than relying on a single sale.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003eResMed's customer relationships are built around \u003cstrong\u003elong-term therapy adherence\u003c\/strong\u003e, \u003cstrong\u003edigital monitoring\u003c\/strong\u003e, and \u003cstrong\u003erecurring software support\u003c\/strong\u003e. The model depends on keeping patients using therapy, clinicians seeing usable data, and healthcare organizations staying on subscription platforms.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOngoing therapy support and education\u003c\/strong\u003e is the core relationship in sleep and respiratory care. ResMed's devices, masks, and connected software are designed to keep patients in treatment over months and years, not just at the point of sale. In academic work, this matters because adherence drives repeat device, mask, and accessory demand, while also supporting better clinical outcomes.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTherapy support is tied to chronic conditions, especially obstructive sleep apnea and chronic obstructive pulmonary disease.\u003c\/li\u003e\n \u003cli\u003eEducation focuses on setup, mask fit, comfort, and correct use, which are all linked to continuation rates.\u003c\/li\u003e\n \u003cli\u003eCare teams and providers use patient feedback and usage data to reduce drop-off after therapy start.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDigital engagement via connected-care tools\u003c\/strong\u003e is a major relationship layer. ResMed uses cloud-linked workflows so patients, clinicians, and care providers can interact without waiting for office visits. This shifts the relationship from one-time hardware delivery to ongoing digital contact.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRelationship channel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer group\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRelationship purpose\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBusiness effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConnected-care software\u003c\/td\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003eUsage feedback, coaching, and adherence support\u003c\/td\u003e\n \u003ctd\u003eHigher therapy persistence and lower churn\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician dashboards\u003c\/td\u003e\n\u003ctd\u003eHealthcare providers\u003c\/td\u003e\n\u003ctd\u003eRemote monitoring and treatment adjustment\u003c\/td\u003e\n \u003ctd\u003eMore efficient care delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscription software support\u003c\/td\u003e\n\u003ctd\u003eSoftware customers\u003c\/td\u003e\n\u003ctd\u003eImplementation, training, and account support\u003c\/td\u003e\n \u003ctd\u003eRenewal potential and recurring revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdherence-focused patient personalization\u003c\/strong\u003e is a practical part of the model. ResMed's relationship strategy depends on tailoring support to the patient's usage patterns, comfort issues, and therapy stage. That can include reminders, data-driven coaching, and adjustments based on device use. This is important because sleep therapy is highly sensitive to early abandonment and comfort problems.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePersonalization reduces friction during the first weeks of treatment.\u003c\/li\u003e\n \u003cli\u003ePersonalization supports mask comfort and nightly use consistency.\u003c\/li\u003e\n \u003cli\u003ePersonalization gives providers better information for follow-up care.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAccount management for software customers\u003c\/strong\u003e is the relationship model on the enterprise side. ResMed's software customers need onboarding, training, technical support, and renewal management. This is a service-heavy relationship, so retention depends on implementation quality, uptime, workflow fit, and ongoing customer success work.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSoftware account stage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eResMed relationship activity\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnboarding\u003c\/td\u003e\n\u003ctd\u003eSetup, training, workflow integration\u003c\/td\u003e\n\u003ctd\u003eDetermines first-use adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive use\u003c\/td\u003e\n\u003ctd\u003eSupport, issue resolution, product updates\u003c\/td\u003e\n \u003ctd\u003eSupports renewal and expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewal\u003c\/td\u003e\n\u003ctd\u003eValue review, contract management\u003c\/td\u003e\n\u003ctd\u003eProtects recurring revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eResMed operates in more than 140 countries\u003c\/strong\u003e, which makes localized relationship management important. Clinical workflows, reimbursement rules, and language needs differ by market, so customer relationships have to be adapted by region and care setting.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatients need simple setup and easy support.\u003c\/li\u003e\n \u003cli\u003eClinicians need fast access to therapy data.\u003c\/li\u003e\n \u003cli\u003eSoftware customers need implementation and renewal support.\u003c\/li\u003e\n \u003cli\u003eRegional differences require local account management and service delivery.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eResMed Inc. - Canvas Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e$4.685 billion\u003c\/strong\u003e in fiscal 2024 revenue shows that ResMed Inc. depends on a channel mix built around provider sales, digital access, and post-acute care software rather than consumer retail. Its channels matter because they shape product adoption, recurring use, and the company's ability to reach patients after diagnosis.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole in ResMed Inc. business model\u003c\/th\u003e\n\u003cth\u003eChannel format\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales to providers\u003c\/td\u003e\n\u003ctd\u003eReaches sleep physicians, hospitals, durable medical equipment providers, and home medical equipment providers\u003c\/td\u003e\n \u003ctd\u003eSales teams, account management, clinical support\u003c\/td\u003e\n \u003ctd\u003eDrives prescription access and device placement\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital sleep-health platforms\u003c\/td\u003e\n\u003ctd\u003eSupports patient engagement, therapy adherence, and remote monitoring\u003c\/td\u003e\n \u003ctd\u003eConnected software, mobile apps, cloud services\u003c\/td\u003e\n \u003ctd\u003eCreates repeat usage and data visibility\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. distribution center network\u003c\/td\u003e\n\u003ctd\u003eMoves devices, masks, and accessories to providers and home-care customers\u003c\/td\u003e\n \u003ctd\u003eWarehousing, fulfillment, logistics\u003c\/td\u003e\n\u003ctd\u003eSupports delivery speed and service reliability\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome-care and out-of-hospital software channels\u003c\/td\u003e\n \u003ctd\u003eServes durable medical equipment and post-acute workflows\u003c\/td\u003e\n \u003ctd\u003eSoftware platforms for operations and patient management\u003c\/td\u003e\n \u003ctd\u003eLinks sales to recurring software revenue\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical and education partnerships\u003c\/td\u003e\n\u003ctd\u003eBuilds awareness, training, and adoption among clinicians\u003c\/td\u003e\n \u003ctd\u003ePrograms with providers, labs, and care networks\u003c\/td\u003e\n \u003ctd\u003eIncreases diagnosis, prescribing, and adherence\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect sales to providers\u003c\/strong\u003e are the core channel for ResMed Inc. This route connects the company to sleep physicians, hospitals, durable medical equipment providers, and home medical equipment providers that prescribe, dispense, and support therapy. In this model, a provider relationship is not just a sales contact; it is the entry point for device placement, mask selection, and long-term patient follow-up. For academic analysis, this channel shows how a medical device company sells through clinical decision-makers instead of only through retailers.\u003c\/p\u003e\n\n\u003cp\u003eThis channel is important because device adoption depends on prescription-based care. ResMed Inc. must persuade providers that its devices, masks, and software are worth recommending and supporting over competing systems. That makes clinical trust part of the sales process. It also means the channel is tied to reimbursement rules, payer requirements, and the pace of diagnosis. When a provider network expands or becomes more efficient, device volumes can rise without ResMed Inc. needing a retail store network.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSleep physicians influence diagnosis and treatment initiation.\u003c\/li\u003e\n \u003cli\u003eDurable medical equipment providers handle dispensing and setup.\u003c\/li\u003e\n \u003cli\u003eHome medical equipment providers support ongoing therapy use.\u003c\/li\u003e\n \u003cli\u003eHospital and post-acute relationships widen access to patients after discharge.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDigital sleep-health platforms\u003c\/strong\u003e are a second channel layer that links ResMed Inc. with patients and providers after the initial sale. These platforms support setup, adherence tracking, and remote communication, which matters because sleep apnea therapy depends on daily use. In business model terms, digital channels increase the value of the device by keeping the patient connected to care. They also make the channel less transactional and more recurring.\u003c\/p\u003e\n\n\u003cp\u003eFor students writing about the business model, this channel is useful because it shows how hardware and software work together. A device sale can lead to ongoing software engagement, while data feedback can help providers monitor adherence. That helps ResMed Inc. build switching costs, because patients and providers who rely on connected workflows are less likely to move away. The channel also supports product bundling across devices, masks, and services.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eU.S. distribution center network\u003c\/strong\u003e is a logistics channel that supports supply reliability and speed. In a medical device business, fulfillment quality affects whether providers and patients receive masks, devices, and replacement parts on time. That matters because therapy continuity depends on timely replenishment. A distribution network also lowers the friction of serving a large installed base, especially for recurring accessories.\u003c\/p\u003e\n\n\u003cp\u003eThis channel is strategic because it affects service levels, not just delivery costs. If a patient needs a replacement mask or part, the ability to ship quickly can reduce therapy interruption. That supports adherence and reduces churn. For academic work, this is a strong example of how distribution is part of the value proposition in healthcare, not just back-office infrastructure.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHome-care and out-of-hospital software channels\u003c\/strong\u003e connect ResMed Inc. to care settings where patients are managed outside acute hospitals. These channels matter because a large share of respiratory and sleep therapy happens at home, through durable medical equipment workflows and remote care coordination. Software becomes a channel because it is the way ResMed Inc. reaches providers with scheduling, documentation, onboarding, and patient-management functions.\u003c\/p\u003e\n\n\u003cp\u003eThis channel is especially important for recurring revenue logic. Software can be billed differently from hardware, and it can deepen the customer relationship after the initial sale. In business model analysis, that means the channel does not just move products; it also captures data and supports retention. It helps explain why ResMed Inc. is more than a device company.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel type\u003c\/th\u003e\n\u003cth\u003eCustomer reached\u003c\/th\u003e\n\u003cth\u003eBusiness effect\u003c\/th\u003e\n\u003cth\u003eAcademic use\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvider sales\u003c\/td\u003e\n\u003ctd\u003eClinicians, DME providers, HME providers\u003c\/td\u003e\n \u003ctd\u003ePrescription access and product placement\u003c\/td\u003e\n \u003ctd\u003eShows clinical-to-commercial conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital platforms\u003c\/td\u003e\n\u003ctd\u003ePatients and providers\u003c\/td\u003e\n\u003ctd\u003eAdherence support and data capture\u003c\/td\u003e\n\u003ctd\u003eShows software as a channel and retention tool\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution centers\u003c\/td\u003e\n\u003ctd\u003eProviders and patients\u003c\/td\u003e\n\u003ctd\u003eFast delivery and replenishment\u003c\/td\u003e\n\u003ctd\u003eShows logistics as part of service quality\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome-care software\u003c\/td\u003e\n\u003ctd\u003ePost-acute care organizations\u003c\/td\u003e\n\u003ctd\u003eWorkflow integration and recurring use\u003c\/td\u003e\n\u003ctd\u003eShows recurring revenue support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEducation partnerships\u003c\/td\u003e\n\u003ctd\u003eClinicians and care teams\u003c\/td\u003e\n\u003ctd\u003eTraining and adoption\u003c\/td\u003e\n\u003ctd\u003eShows demand creation through trust\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical and education partnerships\u003c\/strong\u003e are a demand-creation channel because they build knowledge before the sale happens. In sleep medicine and respiratory care, clinicians often need education on diagnosis, therapy setup, and adherence support before they prescribe or recommend equipment. Partnerships with providers, labs, and care networks help ResMed Inc. shape clinical practice and make therapy easier to start and maintain.\u003c\/p\u003e\n\n\u003cp\u003eThis channel matters because medical device adoption is not only a product decision. It is also a training and workflow decision. If clinicians understand therapy benefits and setup steps, they are more likely to recommend use and support long-term adherence. That helps ResMed Inc. on both the commercial side and the clinical side. For an essay or case study, this channel shows how education works as part of go-to-market strategy in healthcare.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eClinical education supports diagnosis and treatment initiation.\u003c\/li\u003e\n \u003cli\u003eProvider partnerships improve referral flow.\u003c\/li\u003e\n \u003cli\u003eTraining reduces setup friction for patients.\u003c\/li\u003e\n \u003cli\u003eBetter adherence can support repeat accessory demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eResMed Inc. serves customers in more than \u003cstrong\u003e140 countries\u003c\/strong\u003e, so its channels must work across different reimbursement systems, provider models, and care settings. That makes channel design a global operating issue, not just a U.S. sales issue. The same product can move through different channel structures depending on the market, which is why provider relationships, software access, and logistics all need to work together.\u003c\/p\u003e\n\n\u003cp\u003eIn channel terms, ResMed Inc. captures value in three ways: through device sales to providers, through recurring software and digital engagement, and through replenishment of masks and accessories. That mix is why channels are central to the business model. The company's fiscal 2024 revenue of \u003cstrong\u003e$4.685 billion\u003c\/strong\u003e shows the scale of that model, but the channel structure explains how the revenue reaches the customer in the first place.\u003c\/p\u003e\n\u003ch2\u003eResMed Inc. - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eSleep apnea patients\u003c\/strong\u003e are the largest demand pool for ResMed Inc. because obstructive sleep apnea is a chronic condition that usually needs long-term device use, mask replacement, and ongoing monitoring. A widely used global estimate places obstructive sleep apnea at \u003cstrong\u003e936 million\u003c\/strong\u003e adults aged 30 to 69 years worldwide, which matters because ResMed Inc. sells into a recurring-use market rather than a one-time purchase market.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer segment\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRelevant real-life number\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eBusiness meaning\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep apnea patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e936 million\u003c\/strong\u003e adults aged 30 to 69 years worldwide\u003c\/td\u003e\n \u003ctd\u003eLarge addressable pool for CPAP, masks, accessories, and digital adherence support\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRLS therapy patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5%\u003c\/strong\u003e to \u003cstrong\u003e10%\u003c\/strong\u003e of adults\u003c\/td\u003e\n \u003ctd\u003eSmaller but recurring medication and symptom-management segment\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome-care providers and clinics\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e of prescription and setup-linked therapy delivery flows\u003c\/td\u003e\n \u003ctd\u003ePurchase and reimbursement gatekeepers for device initiation and follow-up\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOut-of-hospital care operators\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13%\u003c\/strong\u003e of U.S. adults aged \u003cstrong\u003e18\u003c\/strong\u003e and older use home health care in a given year\u003c\/td\u003e\n \u003ctd\u003eSupports ResMed Inc. software, care coordination, and post-acute workflows\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResidential care software customers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e65\u003c\/strong\u003e and older population group\u003c\/td\u003e\n \u003ctd\u003eTechnology buyers serving aging patients and facilities with recurring workflow needs\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eSleep apnea patients\u003c\/strong\u003e are not one uniform group. The business is shaped by adults with diagnosed obstructive sleep apnea, people still being screened, and patients who stop and restart therapy. The economic logic is simple: a CPAP mask, tubing, filters, and related accessories wear out and are replaced over time, while software and remote monitoring create repeated touchpoints. For academic work, this segment is useful because it links disease prevalence to recurring revenue and compliance behavior.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e936 million\u003c\/strong\u003e adults aged 30 to 69 years worldwide are often cited as the obstructive sleep apnea addressable population.\u003c\/li\u003e\n \u003cli\u003eThe therapy model is repeated use, not a one-time sale.\u003c\/li\u003e\n \u003cli\u003ePatient retention matters because missed nights reduce equipment use and follow-on accessory demand.\u003c\/li\u003e\n \u003cli\u003eRemote monitoring makes adherence measurable through usage data rather than self-reporting alone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eHome-care providers and clinics\u003c\/strong\u003e are a separate customer segment because they often control setup, education, insurance paperwork, and follow-up. In this channel, the buyer is not always the end patient. The provider decides which device is dispensed, which mask is fitted, and how monitoring is handled. This matters strategically because distributor and clinic relationships can determine device availability, reimbursement speed, and switching costs.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eThey manage initial setup and ongoing follow-up for CPAP therapy.\u003c\/li\u003e\n \u003cli\u003eThey are linked to reimbursement documentation and prescription fulfillment.\u003c\/li\u003e\n \u003cli\u003eThey need products that are easy to fit, train on, and support remotely.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOut-of-hospital care operators\u003c\/strong\u003e include post-acute providers, home health organizations, and other non-hospital settings that manage patients after discharge. In the United States, \u003cstrong\u003e13%\u003c\/strong\u003e of adults aged \u003cstrong\u003e18\u003c\/strong\u003e and older use home health care in a given year, which shows the size of the adjacent care environment ResMed Inc. can serve through software and care coordination tools. This segment matters because hospitals want lower readmissions, while operators want tighter workflows and fewer manual steps.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e13%\u003c\/strong\u003e of U.S. adults aged \u003cstrong\u003e18\u003c\/strong\u003e and older use home health care in a given year.\u003c\/li\u003e\n \u003cli\u003eDemand is driven by discharge management, chronic disease follow-up, and care coordination.\u003c\/li\u003e\n \u003cli\u003eSoftware value comes from workflow speed, documentation, and visibility across care teams.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eResidential care software customers\u003c\/strong\u003e are facilities and operators serving older adults, including assisted living and similar settings where workflow software supports intake, staffing, patient records, and communication. The business case is tied to aging demographics. In the United States, people aged \u003cstrong\u003e65\u003c\/strong\u003e and older are the core population for residential care demand, and this age group is also more likely to need respiratory and sleep-related support. This makes the segment relevant to ResMed Inc. where software links clinical activity, operational records, and recurring service relationships.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eResidential care software customer type\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eTypical need\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssisted living operators\u003c\/td\u003e\n\u003ctd\u003eRecurring resident records and care coordination\u003c\/td\u003e\n \u003ctd\u003eWorkflow tools and communication systems\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-acute care organizations\u003c\/td\u003e\n\u003ctd\u003eTransition management after hospitalization\u003c\/td\u003e\n \u003ctd\u003eDocumentation and patient tracking\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResidential care administrators\u003c\/td\u003e\n\u003ctd\u003eStaffing and compliance pressure\u003c\/td\u003e\n\u003ctd\u003eAdministrative software and scheduling support\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRLS therapy patients\u003c\/strong\u003e are a smaller but important segment because restless legs syndrome is chronic and can require ongoing treatment. The disorder is often described as affecting \u003cstrong\u003e5%\u003c\/strong\u003e to \u003cstrong\u003e10%\u003c\/strong\u003e of adults, with more severe persistent cases representing a narrower group. For ResMed Inc., this segment matters because it broadens the company beyond sleep apnea and creates cross-sell potential into patients who already interact with sleep-health providers.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e5%\u003c\/strong\u003e to \u003cstrong\u003e10%\u003c\/strong\u003e of adults may have restless legs syndrome.\u003c\/li\u003e\n \u003cli\u003eChronic symptoms support repeat care interactions rather than one-time treatment.\u003c\/li\u003e\n \u003cli\u003eSegment overlap with sleep clinics can lower acquisition cost for patient outreach.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCustomer-segment overlap\u003c\/strong\u003e is central to this business model because the same person can move across segments. A patient can start in a sleep clinic, switch to home care, receive support through out-of-hospital care channels, and later interact with residential care software if aging or frailty changes care needs. That overlap matters because it raises lifetime value per patient and gives ResMed Inc. more than one way to serve the same user over time.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSegment overlap\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOperational effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep apnea patients and home-care providers\u003c\/td\u003e\n \u003ctd\u003eDevice dispensing, setup, and refill cycle\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep apnea patients and clinics\u003c\/td\u003e\n\u003ctd\u003eDiagnosis, titration, and follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOut-of-hospital care operators and residential care software customers\u003c\/td\u003e\n \u003ctd\u003eWorkflow, documentation, and care continuity\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRLS therapy patients and sleep clinics\u003c\/td\u003e\n\u003ctd\u003eSecondary diagnostic and treatment pathway\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRecurring revenue logic\u003c\/strong\u003e depends on patient size, therapy persistence, and replacement cycles. The business is stronger when customers remain in therapy long enough to replace masks, cushions, filters, and related supplies. It is also stronger when providers and software customers keep patient data inside the same workflow system, because that raises switching costs and reduces churn.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eResMed does not present a standalone public line item for acquisition and integration costs in its core operating expenses, so the cost structure is mainly visible through R\u0026amp;D, SG\u0026amp;A, manufacturing, logistics, and compliance spending in its annual and quarterly reporting.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCost Structure Item\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life disclosed number\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eReporting basis\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spending\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed here without a filed period-specific figure\u003c\/td\u003e\n \u003ctd\u003eOperating expense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A and marketing\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed here without a filed period-specific figure\u003c\/td\u003e\n \u003ctd\u003eOperating expense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition and integration costs\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed here without a filed period-specific figure\u003c\/td\u003e\n \u003ctd\u003eNon-recurring or acquisition-related items\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and logistics\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed here without a filed period-specific figure\u003c\/td\u003e\n \u003ctd\u003eCost of goods sold and operating support\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory and legal compliance costs\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed here without a filed period-specific figure\u003c\/td\u003e\n \u003ctd\u003eOperating expense and compliance support\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eR\u0026amp;D spending\u003c\/strong\u003e is one of the most important fixed cost buckets in ResMed's model because the company depends on product design, software, cloud connectivity, and device iteration. In this business, R\u0026amp;D supports devices, masks, digital care tools, and data-enabled therapies, so it directly affects long-term product differentiation and replacement cycles.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eEngineering headcount\u003c\/li\u003e\n\u003cli\u003eClinical testing\u003c\/li\u003e\n\u003cli\u003eSoftware development\u003c\/li\u003e\n\u003cli\u003eProduct verification and validation\u003c\/li\u003e\n\u003cli\u003eCybersecurity and connected-device development\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSG\u0026amp;A and marketing\u003c\/strong\u003e cover selling, general, and administrative functions, which usually include sales teams, customer support, general corporate overhead, and product promotion. For a global medical technology company, this cost base matters because reimbursement, physician adoption, sleep clinic relationships, and payer access all require sales coverage and market education.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcquisition and integration costs\u003c\/strong\u003e rise when a company buys software, data, device, or services assets and then folds them into its operating platform. In ResMed's case, these costs matter because the company has expanded beyond hardware into digital care and connected therapy workflows, which increases integration work across software, operations, and compliance systems.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and logistics\u003c\/strong\u003e are central to the cost structure because ResMed sells physical devices, masks, and accessories. That means costs are tied to component sourcing, assembly, quality control, warehousing, freight, inventory management, and delivery to hospitals, distributors, and patients.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eComponent procurement\u003c\/li\u003e\n\u003cli\u003eAssembly and testing\u003c\/li\u003e\n\u003cli\u003eInventory holding\u003c\/li\u003e\n\u003cli\u003eFreight and shipping\u003c\/li\u003e\n\u003cli\u003eWarehousing and distribution\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory and legal compliance costs\u003c\/strong\u003e are structurally important because ResMed operates in a regulated medical device environment. These costs include product registration, quality systems, audit readiness, post-market surveillance, legal review, and data protection work, especially because connected devices and digital health platforms increase privacy and cybersecurity obligations.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBusiness Model Canvas cost structure logic\u003c\/strong\u003e for ResMed is driven by a mix of recurring operating expense and product-level cost. The biggest economic pressure points are typically R\u0026amp;D, global selling infrastructure, regulated manufacturing, and compliance maintenance, because these are required to keep products approved, distributed, and clinically trusted.\u003c\/p\u003e\u003ch2\u003eResMed Inc. - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$800M\u003c\/strong\u003e for Brightree and \u003cstrong\u003e$750M\u003c\/strong\u003e for MatrixCare are the clearest real-world reference points for the two software revenue engines in ResMed Inc.'s model.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSleep device sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eResMed Inc. generates device revenue from sleep apnea and respiratory care equipment. This is the largest hardware-style cash engine in the business model, and it depends on repeat clinical diagnosis, patient initiation, and replacement cycles rather than one-time household purchases.\u003c\/p\u003e\n\u003cp\u003eThe core revenue logic is tied to prescription-based therapy. A device sale is usually only the first transaction in a longer chain that can include masks, tubing, humidifiers, and other replacement parts.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue stream\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhat it means for the model\u003c\/strong\u003e\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrightree acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$800M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports software-linked device and therapy workflows\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrixCare acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$750M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports residential care software tied to care delivery\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003eDevice sales are recurring at the patient level because therapy use creates replacement demand.\u003c\/li\u003e\n \u003cli\u003eDevices support downstream sales of masks and accessories.\u003c\/li\u003e\n \u003cli\u003eDevice revenue is tied to regulated care pathways, which matters for access and reimbursement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMasks and accessories sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMasks and accessories are a separate revenue stream because they wear out, need replacement, and often generate more frequent purchases than the main device. In the revenue model, this makes accessories a high-frequency add-on stream linked to the installed base.\u003c\/p\u003e\n\u003cp\u003eThis stream matters because it usually deepens customer lifetime value. A single device user can produce multiple accessory transactions over time, which smooths revenue compared with pure device replacement cycles.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eReplacement parts create repeat sales after the initial device purchase.\u003c\/li\u003e\n \u003cli\u003eAccessory demand depends on the size of the active therapy user base.\u003c\/li\u003e\n \u003cli\u003eMask fit and comfort can influence retention and reorder behavior.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eResidential care software revenue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eResidential care software revenue comes from software used in care settings such as senior living and long-term care. ResMed Inc. expanded this channel through MatrixCare, which it bought for \u003cstrong\u003e$750M\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThis stream is different from hardware because it is software-based and usually tied to subscriptions, implementation, support, and renewals. That makes it more predictable than one-time equipment sales if retention stays high.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSoftware line\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAcquisition value\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue logic\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResidential care software\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$750M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSubscription and service revenue from care settings\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOut-of-hospital software\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$800M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWorkflow and billing revenue from post-acute care providers\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOut-of-hospital software revenue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOut-of-hospital software revenue comes from software used by home medical equipment providers and other care organizations outside the hospital. Brightree is the main reference point here, with a purchase price of \u003cstrong\u003e$800M\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThis stream matters because it links software to the operational needs of providers who manage ordering, billing, fulfillment, and documentation. That creates recurring revenue potential if customers keep renewing contracts and adding modules.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eRevenue is tied to software subscriptions and service contracts.\u003c\/li\u003e\n \u003cli\u003eProvider workflows make switching costs meaningful.\u003c\/li\u003e\n \u003cli\u003eBilling and fulfillment software can be sticky because it sits inside daily operations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInternational therapy sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eInternational therapy sales cover device, mask, and software revenue generated outside the United States. For a company like ResMed Inc., this stream matters because therapy adoption, reimbursement systems, and care delivery differ by country, so geographic mix can change growth and margin patterns.\u003c\/p\u003e\n\u003cp\u003eThe revenue model is not just about selling more units. It is also about how fast therapy adoption rises in each market, how local distributors operate, and how much of the patient pathway is covered by public or private reimbursement.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eInternational sales diversify revenue beyond the U.S. market.\u003c\/li\u003e\n \u003cli\u003eTherapy sales abroad can be affected by reimbursement structure.\u003c\/li\u003e\n \u003cli\u003eMarket-by-market adoption rates can change the balance between device sales and software sales.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601620005013,"sku":"rmd-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/rmd-business-model-canvas.png?v=1740210892","url":"https:\/\/dcf-model.com\/pt\/products\/rmd-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}